■本研究旨在观察和比较玻璃体腔注射康柏西普(IVC)联合全视网膜光凝(PRP)与PRP单药治疗的高危增生性糖尿病视网膜病变(PDR)患者的视网膜静脉直径变化和其他基本指标。
■对接受特定治疗并随访24个月的高危PDR患者的数据进行了回顾性分析。在82例高危PDR患者中,50只眼接受PRP联合IVC,而32只眼单独接受PRP。在24个月的随访期间,最佳矫正视力(BCVA)的变化,中央凹厚度(CFT),视网膜静脉直径,微动脉瘤数量(MA),新生血管(NV)面积,硬渗出物(HE)面积,中央凹无血管区(FAZ)的大小,浅表毛细血管丛(SCP)血流密度,在基线和治疗后6,12,18和24个月时,记录并比较两组的不良反应.分析各观察指标与静脉内径的关系。
■在24个月的随访期间,BCVA的重大改进,CFT,视网膜静脉直径,MA的数量,NV区域,他地区,FAZ,治疗后IVC+PRP组观察到SCP。PRP组仅显示NV和HE区域的显著减少。IVC+PRP组在改善静脉直径方面明显优于PRP组,MA的数量,他地区。然而,两组间NV面积减少无统计学差异.
■在高风险PDR的治疗中,IVC+PRP疗法比PRP单一疗法具有显著优势。IVC+PRP治疗可以逆转糖尿病引起的视网膜静脉改变,恢复形态和功能。
This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy.
A retrospective analysis was conducted on data from patients with high-risk PDR who received specific treatment and were followed up for 24 months. Among 82 patients with high-risk PDR, 50 eyes received PRP combined with IVC, whereas 32 eyes received PRP alone. During the 24-month follow-up period, changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), retinal vein diameter, number of microaneurysms (MA), neovascularization (NV) area, hard exudate (HE) area, size of the foveal avascular zone (FAZ), superficial capillary plexus (SCP) blood flow density, and adverse effects were recorded and compared between the two groups at baseline and at 6, 12, 18, and 24 months after treatment. The relationship between each observation index and vein diameter was also analyzed.
During the 24-month follow up, significant improvements in the BCVA, CFT, retinal vein diameter, number of MAs, NV area, HE area, FAZ, and SCP were observed in the IVC+PRP group after treatment. The PRP group only showed significant reductions in NV and HE areas. The IVC+PRP group showed significant superiority over the PRP group in improving the vein diameter, number of MA, and HE area. However, no statistically significant difference in NV area reduction was found between the groups.
In the treatment of high-risk PDR, IVC+PRP therapy has a significant advantage over PRP monotherapy. IVC+PRP therapy may reverse diabetes-induced retinal vein changes, restoring morphology and function.